A former study evaluated the roles of four multidrug resistance-related proteins, namely multidrug resistance protein 1 (MDR1), breast cancer resistance protein (BCRP), multidrug resistance-related protein (MRP1), and lung resistance-related protein (LRP), in the MDR mechanism of the multidrug resistant hepatoma HepG2/ADM cell line and proposed that up-regulated MDR1 and BCRP are responsible for the MDR of hepatocellular carcinoma. This work aims to confirm that assumption in vivo and in clinical specimens.
Methods
First, the chemotherapeutic resistance of subcutaneous HepG2/ADM tumor and hepatocellular carcinoma samples post-transarterial chemoembolization (TACE) was determined by MTT, contrary to subcutaneous HepG2 tumor and hepatocellular carcinoma samples without TACE, respectively. Then, the mRNA and protein differential expression of the four genes between the MDR tissues and drug-sensitive tissues were quantitatively investigated by real-time RT-PCR and enhanced chemiluminescence western blot analysis, respectively.
Results
1) mRNA expression of BCRP and MDR1 was respectively amplified 38.3 and 20.1 fold in tumors of HepG2/ADM mice compared to those of HepG2 mice, whereas they were respectively augmented for 14.6 and 9.3 times in TACE samples, contrary to the tumor tissues without TACE. 2) The protein presence of MDR1 and BCRP in MDR tumors was also significantly higher than those in the control group in vivo and in clinical specimens. 3) The mRNA expressions of MDR1 and BCRP were correlated to their protein levels.
Conclusions
The study showed that MDR1 and BCRP may be the most important factors for drug resistance in hepatocellular carcinoma. Moreover, the positive correlation between their mRNA and protein expression indicates the easy prediction of HCC MDR and possible inhibitive target of drug resistance at multi-levels.
ChengB.Q., JiaC.Q., LiuC.T., FanW., WangQ.L., ZhangZ.L., YiC.H.: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA, 299: 1669–1677, 2008.
3.
LlovetJ.M., BruixJ.: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 37: 429–442, 2003.
4.
YeoW., MokT.S., ZeeB., LeungT.W., LaiP.B., LauW.Y., KohJ., MoF.K., YuS.C., ChanA.T., HuiP., MaB., LamK.C., HoW.M., WongH.T., TangA., JohnsonP.J.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst, 97: 1532–1538, 2005.
5.
LiQ., WangJ., SunY., CuiY.L., JuziJ.T., QianB.Y., HaoX.S.: Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig Surg, 23: 235–240, 2006.
6.
DoyleL.A., YangW., AbruzzoL.V., KrogmannT., GaoY., RishiA.K., RossD.D.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 95: 15665–15670, 1998.
7.
UgglaB., StahlE., WagsaterD., PaulC., KarlssonM.G., SirsjoA., TidefeltU.: BCRP mRNA expression vs. clinical outcome in 40 adult AML patients. Leuk Res, 29: 141–146, 2005.
8.
AbbottB.L., ColapietroA.M., BarnesY., MariniF., AndreeffM., SorrentinoB.P.: Low levels of ABCG2 expression in adult AML blast samples. Blood, 100: 4594–4601, 2002.
9.
LeeJ.S., ScalaS., MatsumotoY., DicksteinB., RobeyR., ZhanZ., AltenbergG., BatesS.E.: Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem, 65: 513–526, 1997.
10.
CallenD.F., BakerE., SimmersR.N., SeshadriR., RoninsonI.B.: Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet, 77: 142–144, 1987.
11.
ChenC.J., ChinJ.E., UedaK., ClarkD.P., PastanI., GottesmanM.M., RoninsonI.B.: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381–389, 1986.
12.
van der KolkD.M., VellengaE., SchefferG.L., MullerM., BatesS.E., ScheperR.J., de VriesE.G.: Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood, 99: 3763–3770, 2002.
13.
ColeS.P., BhardwajG., GerlachJ.H., MackieJ.E., GrantC.E., AlmquistK.C., StewartA.J., KurzE.U., DuncanA.M., DeeleyR.G.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258: 1650–1654, 1992.
14.
SchefferG.L., WijngaardP.L., FlensM.J., IzquierdoM.A., SlovakM.L., PinedoH.M., MeijerC.J., CleversH.C., ScheperR.J.: The drug resistance-related protein LRP is the human major vault protein. Nat Med, 1: 578–582, 1995.
15.
HananiaE.G., FuS., ZuZ., Hegewisch-BeckerS., KorblingM., HesterJ., DurettA., AndreeffM., MechetnerE., HolzmayerT.: Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther, 2: 285–294, 1995.
16.
TanakaY., SlittA.L., LeazerT.M., MaherJ.M., KlaassenC.D.: Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun, 326: 181–187, 2005.
17.
LiG., ChenX., WangQ., XuZ., ZhangW., YeL.: The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci, 27: 173–175, 2007.
18.
TaipalensuuJ., TavelinS., LazorovaL., SvenssonA.C., ArturssonP.: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci, 21: 69–75, 2004.
19.
RybarovaS., HodorovaI., HajdukovaM., SchmidtovaK., MojzisJ., KajoK., KviatkovskaZ., PlankL., BenickyM., MirossayA., BirosE., BobrovN., WagnerovaM., BercA., MirossayL.: Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma, 53: 128–135, 2006.
20.
KamimotoY., GatmaitanZ., HsuJ., AriasI.M.: The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem, 264: 11693–11698, 1989.
21.
MiyakeK., MickleyL., LitmanT., ZhanZ., RobeyR., CristensenB., BrangiM., GreenbergerL., DeanM., FojoT., BatesS.E.: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res, 59: 8–13, 1999.
22.
MaliepaardM., van GastelenM.A., de JongL.A., PluimD., van WaardenburgR.C., Ruevekamp-HelmersM.C., FlootB.G., SchellensJ.H.: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res, 59: 4559–4563, 1999.
23.
VolkE.L., FarleyK.M., WuY., LiF., RobeyR.W., SchneiderE.: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res, 62: 5035–5040, 2002.
24.
SchneiderE., HortonJ.K., YangC.H., NakagawaM., CowanK.H.: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res, 54: 152–158, 1994.
25.
IzquierdoM.A., van der ZeeA.G., VermorkenJ.B., van der ValkP., BelienJ.A., GiacconeG., SchefferG.L., FlensM.J., PinedoH.M., KenemansP., MeijerCJLM, de VriesE.G.E., ScheperR.J.: Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst, 87: 1230–1237, 1995.
26.
ArtsH.J., KatsarosD., de VriesE.G., MassobrioM., GentaF., DaneseS., ArisioR., ScheperR.J., KoolM., SchefferG.L., WillemseP.H., van der ZeeA.G., SuurmeijerA.J.: Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res, 5: 2798–2805, 1999.
27.
SuvannasankhaA., MindermanH., O'LoughlinK.L., NakanishiT., GrecoW.R., RossD.D., BaerM.R.: Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia, 18: 1252–1257, 2004.
28.
AlbermannN., Schmitz-WinnenthalF.H., Z'graggenK., VolkC., HoffmannM.M., HaefeliW.E., WeissJ.: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol, 70: 949–958, 2005.
29.
ZhouX.F., YangX., WangQ., CoburnR.A., MorrisM.E.: Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos, 33: 1220–1228, 2005.
30.
WalterR.B., PirgaJ.L., CronkM.R., MayerS., AppelbaumF.R., BankerD.E.: PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood, 106: 3584–3593, 2005.
31.
ZhangS., YangX., CoburnR.A., MorrisM.E.: Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol, 70: 627–639, 2005.
32.
ChangC.C., LiangY.C., KlutzA., HsuC.I., LinC.F., MoldD.E., ChouT.C., LeeY.C., HuangR.C.: Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol, 58: 640–653, 2006.
33.
ElkindN.B., SzentpeteryZ., ApatiA., Ozvegy-LaczkaC., VaradyG., UjhellyO., SzaboK., HomolyaL., VaradiA., BudayL., KeriG., NemetK., SarkadiB.: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res, 65: 1770–1777, 2005.
34.
Munoz-MartinezF., LuP., Cortes-SelvaF., Perez-VictoriaJ.M., JimenezI.A., RaveloA.G., SharomF.J., GamarroF., CastanysS.: Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res, 64: 7130–7138, 2004.
35.
TaharaH., KusuharaH., FuseE., SugiyamaY.: P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos, 33: 963–968, 2005.
36.
CisterninoS., MercierC., BourassetF., RouxF., ScherrmannJ.M.: Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res, 64: 3296–3301, 2004.
37.
BruggerD., BrischweinK., LiuC., BaderP., NiethammerD., GekelerV., BeckJ.F.: Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anticancer Res, 22: 4229–4232, 2002.
38.
Di LeoA., GancbergD., LarsimontD., TannerM., JarvinenT., RouasG., DolciS., LeroyJ.Y., PaesmansM., IsolaJ., PiccartM.J.: HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res, 8: 1107–1116, 2002.
39.
OkadaY., TosakaA., NimuraY., KikuchiA., YoshidaS., SuzukiM.: Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene, 272: 141–148, 2001.
40.
HerzogC.E., HolmesK.A., TuschongL.M., GanapathiR., ZwellingL.A.: Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase II alpha. Cancer Res, 58: 5298–5300, 1998.
41.
ZhangK., WongK.P., ChowP.: Conjugation of chlorambucil with GSH by GST purified from human colon adenocarcinoma cells and its inhibition by plant polyphenols. Life Sci, 72: 2629–2640, 2003.
